Genital Herpes



Maintenance Dose Study of GEN-003 in Subjects With Genital Herpes Infection


Conditions:   Genital Herpes;   HSV-2 Infection
Interventions:   Biological: GEN-003;   Biological: Matrix-M2;   Other: 0.9% normal saline
Sponsor:   Genocea Biosciences, Inc.
Active, not recruiting


The VIBLOK SAfety and perFormancE Trial


Conditions:   HSV-2 Infection;   Genital Herpes
Intervention:   Device: VIBLOK barrier cream
Sponsors:   CLJI Worldwide;   Applied Clinical Services BV;   UMC Utrecht;   University of Rotterdam, The Netherlands;   University of Washington;   EB FlevoResearch BV;   PreCare Trial & Recruitment B.V.
Recruiting


Comparative Effectiveness of Treatment Options for Genital Herpes Infection to Reduce Adverse Pregnancy Outcomes


Conditions:   HSV-2 Infection;   PreTerm Birth;   Pregnancy Complications
Intervention:  
Sponsors:   Kaiser Permanente;   Patient-Centered Outcomes Research Institute
Recruiting


Long-term Follow-up of GEN-003-002 Subjects for Efficacy and Immunogenicity


Condition:   Genital Herpes Simplex Type 2
Intervention:   Biological: Observational
Sponsor:   Genocea Biosciences, Inc.
Completed


Safety and Efficacy Study of Herpes Simplex Virus Type 2 (HSV-2) Therapeutic DNA Vaccine


Condition:   Herpes Genitalis
Interventions:   Biological: VCL-HB01;   Other: Phosphate-buffered saline
Sponsor:   Vical
Active, not recruiting


Evaluating New Formulation of Therapeutic HSV-2 Vaccine


Condition:   Genital Herpes Simplex Type 2
Interventions:   Biological: Matrix-M2;   Biological: GEN-003;   Drug: Placebo
Sponsor:   Genocea Biosciences, Inc.
Completed


Rollover Trial for Placebo Subjects Previously Enrolled Into GEN-003-002 Study


Condition:   Genital Herpes Simplex Type 2
Interventions:   Biological: GEN-003 Vaccine (30μg of each antigen);   Biological: GEN-003 Vaccine (60μg of each antigen);   Biological: Matrix-M2 Adjuvant (25μg);   Biological: Matrix-M2 Adjuvant (50μg);   Biological: Matrix-M2 Adjuvant (75μg)
Sponsor:   Genocea Biosciences, Inc.
Completed


Dose Ranging Safety and Efficacy of Therapeutic HSV-2 Vaccine


Condition:   Genital Herpes Simplex Type 2
Interventions:   Biological: GEN-003 Vaccine (30μg of each antigen);   Biological: GEN-003 Vaccine (60μg of each antigen);   Biological: Matrix-M2 Adjuvant (25μg);   Biological: Matrix-M2 Adjuvant (50μg);   Biological: Matrix-M2 Adjuvant (75μg);   Biological: Placebo
Sponsor:   Genocea Biosciences, Inc.
Completed


Acyclovir Therapy for Genital Herpes Ulcers in HIV Negative African Women


Condition:   Ulcers of Female Genital Organs
Interventions:   Drug: Acyclovir;   Drug: Placebo
Sponsors:   University of North Carolina, Chapel Hill;   National Institute of Allergy and Infectious Diseases (NIAID)
Completed


Study of the Safety of a Particular Herpes Vaccine in Adults With or Without Herpes Infection


Conditions:   Genital Herpes;   Herpes Simplex Virus;   Herpes Simplex Virus Vaccines;   HSV Vaccines;   Herpesvirus Vaccines
Intervention:   Biological: HSV529
Sponsors:   National Institute of Allergy and Infectious Diseases (NIAID);   Sanofi Pasteur, a Sanofi Company
Completed


Special Drug Use Investigation for VALTREX (Valaciclovir) (Suppression Prophylaxis)


Condition:   Genital Herpes
Intervention:   Drug: Valaciclovir Hydrochloride.
Sponsor:   GlaxoSmithKline
Completed


Randomized Trial to Evaluate Suppressive Effect of High-Dose Valacyclovir Versus Once-Daily Valacyclovir on Persons With HSV-2


Condition:   Genital Herpes
Interventions:   Drug: valacyclovir;   Drug: Valacyclovir
Sponsors:   University of Washington;   GlaxoSmithKline
Completed


Can Valacyclovir Delay the Need for Initiation of Human Immunodeficiency Virus (HIV) Treatment in HIV-infected Individuals?


Conditions:   HIV Infection;   Herpes Simplex Type II;   HIV Infections
Interventions:   Drug: valacyclovir;   Drug: Placebo
Sponsors:   University Health Network, Toronto;   CIHR Canadian HIV Trials Network
Active, not recruiting


GUD Clinical and Virologic Response to Acyclovir in HIV Negative African Women


Condition:   Genital Herpes
Interventions:   Drug: acyclovir;   Drug: matching placebo
Sponsors:   University of Washington;   National Institute of Allergy and Infectious Diseases (NIAID);   National Institutes of Health (NIH)
Completed


A Randomized Trial to Evaluated the Suppressive Effect of Acyclovir on Rapidly Cleared HSV-2 Reactivation


Condition:   Genital Herpes
Intervention:   Drug: acyclovir
Sponsors:   University of Washington;   National Institutes of Health (NIH)
Completed


Effect of HSV-2 Suppressive Therapy on Sexual Behavior


Condition:   Genital Herpes
Intervention:   Drug: acyclovir
Sponsors:   University of Washington;   National Institute of Allergy and Infectious Diseases (NIAID)
Active, not recruiting


VALTREX(Valacyclovir) Once Daily for Viral Shedding In Subjects Newly Diagnosed With HSV-2


Condition:   Herpes Labialis
Intervention:   Drug: valacyclovir
Sponsor:   GlaxoSmithKline
Completed



VALTREX Once Daily For Viral Shedding In Herpes Simplex Virus 2 (HSV-2) Seropositive Subjects. VALTREX® Tablet is a Trademark of GlaxoSmithKline Group of Companies.


Condition:   Infections, Herpesviridae
Intervention:   Drug: Valaciclovir
Sponsor:   GlaxoSmithKline
Completed


A Clinical Research Study For The Suppression And Treatment Of Genital Herpes Infection In HIV-Infected Persons


Condition:   Herpes Genitalis
Intervention:   Drug: valacyclovir hydrochloride
Sponsor:   GlaxoSmithKline
Terminated

Refine Your Search Advanced Search